



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

Neovacs to attend ChinaBio® Event May 18 & 19, 2016

Paris and Boston, May 17th, 2016 – Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the [ChinaBio® Partnering Forum](#), being held on May 18- 19 in Suzhou, China.

This forum is dedicated to biotechnology companies from around the world, enabling them to identify and meet local partners. Neovacs will have the opportunity to present its technology, strategy and recent news to prospective strategic partners in China, a region in which there are more than one million Lupus patients.

To further support its growth, Neovacs is seeking new partnerships. To achieve this goal, the company is in discussions with companies in five countries and over the past several months, has signed two new important development and commercialization partnerships with Chong Kun Dang Pharmaceutical Corp. in South Korea and Stellar Biotechnologies in the United States.

In April 2016, Neovacs obtained both authorization from the health authorities of South Korea and IND approval from the U.S. Food and Drug Administration (FDA) for its ongoing Phase IIb clinical trial with IFN α Kinoid to treat Lupus.

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations

Charlène Masson

+33 (0)1 53 10 93 14

cmasson@neovacs.com

Investor Relations / Financial Communications Germany – MC Services

Raimund Gabriel

+49-89-21-02-28-30

raimund.gabriel@mc-services.eu

Press / U.S. Inquiries – The Ruth Group

Lee Roth / Joseph Green

+1-646-536-7012 / 7013

lroth@theruthgroup.com / jgreen@theruthgroup.com